{"nctId":"NCT00136604","briefTitle":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","startDateStruct":{"date":"2006-01-22","type":"ACTUAL"},"conditions":["Whole Cell Pertussis","Haemophilus Influenzae Type b","Hepatitis B","Diphtheria","Tetanus","Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin"],"count":617,"armGroups":[{"label":"ACAC GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix-HepB/Hib-MenAC"]},{"label":"ACHibPS GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Mencevax ACWY","Biological: Tritanrix-HepB/Hiberix"]},{"label":"HibACPS GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix-HepB/Hib-MenAC","Biological: Mencevax ACWY"]},{"label":"HibHibPS GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Mencevax ACWY","Biological: Tritanrix-HepB/Hiberix"]},{"label":"CC GROUP","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix-HepB/Hiberix","Biological: Meningitec"]}],"interventions":[{"name":"Tritanrix-HepB/Hib-MenAC","otherNames":[]},{"name":"Mencevax ACWY","otherNames":[]},{"name":"Tritanrix-HepB/Hiberix","otherNames":[]},{"name":"Meningitec","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Healthy male or female between and including 15 and 24 months of age\n* Having participated in the primary vaccination study DTPW-HBV=HIB-MENAC-TT-003 (eTrack No. 100480)\n\nExclusion criteria:\n\n* Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib) and/or meningococcal serogroups A and/or C disease not foreseen in the protocol, after the date of the study conclusion visit of the primary vaccination study DTPW-HBV=HIB-MENAC-TT-003 (eTrack No. 100480).\n* History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B, Hib and/or meningococcal serogroup A or C disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition.\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures including febrile seizures (at least two events) in infancy.","healthyVolunteers":true,"sex":"ALL","minimumAge":"427 Days","maximumAge":"730 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Meningococcal C Serum Bactericidal Assay (SBA-MenC) Antibody Titers Above the Cut-off Value","description":"Pre-defined assay cut-off value for assessed titers was greater than or equal to (≥) 1:128.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With SBA-MenA Antibody Titers Above the Cut-off Value","description":"Pre-defined assay cut-off value for assessed titers was greater than or equal to (≥) 1:128. Note: For the MenA antibodies with assay on SBA, additional testing were done using a serogroup A strain 3125 (L10 immunotype).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Seroprotected (SPR) Subjects With Anti-Polyribosyl Ribitol Phosphate Anti-(PRP) Antibody Concentrations Above the Cut-off Value","description":"Antibody concentrations cut-off value was ≥ 1 microgram per milliliter (µg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of SPR Subjects With Anti-(PRP) Antibody Concentrations Above Predefined Cut-off Values","description":"Antibody concentrations cut-off values were ≥ 0.15 and ≥ 1 micrograms per milliliter (µg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"88.2","spread":null},{"groupId":"OG003","value":"87.8","spread":null},{"groupId":"OG004","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.572","spread":null},{"groupId":"OG001","value":"4.371","spread":null},{"groupId":"OG002","value":"3.728","spread":null},{"groupId":"OG003","value":"4.498","spread":null},{"groupId":"OG004","value":"4.775","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.798","spread":null},{"groupId":"OG001","value":"168.232","spread":null},{"groupId":"OG002","value":"56.772","spread":null},{"groupId":"OG003","value":"129.222","spread":null},{"groupId":"OG004","value":"115.384","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With SBA-MenC Antibody Titers Above the Cut-off Values","description":"Pre-defined assay cut-off values for assessed titers were greater than or equal to (≥) 1:8 and ≥ 1:128.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"10.7","spread":null},{"groupId":"OG002","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-SBA-MenC Antibody Titers","description":"Antibody titers were presented as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"295.2","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"143.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4891.2","spread":null},{"groupId":"OG001","value":"1868.4","spread":null},{"groupId":"OG002","value":"8068.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Serum Bactericidal Assay Against Meningococcal Serogroup A Using Rabbit Complement (rSBA-MenA) Antibody Titers Above the Pre-defined Cut-off Values","description":"Pre-defined assay cut-off values for assessed titers were greater than or equal to (≥) 1:8 and (≥) 1:128. Note: For the MenA antibodies with assay on SBA, additional testing were done using a serogroup A strain 3125 (L10 immunotype).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"88.6","spread":null},{"groupId":"OG002","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"85.7","spread":null},{"groupId":"OG002","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"54.2","spread":null},{"groupId":"OG002","value":"57.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"42.4","spread":null},{"groupId":"OG002","value":"42.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"70.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-rSBA-MenA Antibody Titers","description":"Antibody titers were presented as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"626.2","spread":null},{"groupId":"OG001","value":"327.2","spread":null},{"groupId":"OG002","value":"468.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1488.8","spread":null},{"groupId":"OG001","value":"3429.6","spread":null},{"groupId":"OG002","value":"411.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141.1","spread":null},{"groupId":"OG001","value":"37.1","spread":null},{"groupId":"OG002","value":"33.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1784.8","spread":null},{"groupId":"OG001","value":"1663.7","spread":null},{"groupId":"OG002","value":"172.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentrations Above the Predefined Cut-off Values","description":"Antibody concentrations cut-off values were ≥ 0.3 and ≥ 2 micrograms per milliliter (µg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSC Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in micrograms/milliliter (µg/ml).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"1.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.71","spread":null},{"groupId":"OG001","value":"25.96","spread":null},{"groupId":"OG002","value":"31.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Anti-polysaccharide A (Anti-PSA) Antibody Concentrations Above the Predefined Cut-off Values","description":"Antibody concentrations cut-off values were ≥ 0.3 and ≥ 2 micrograms per milliliter (µg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"18.4","spread":null},{"groupId":"OG002","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSA Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) ad expressed in micrograms per milliliter ().","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":null},{"groupId":"OG001","value":"0.20","spread":null},{"groupId":"OG002","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.31","spread":null},{"groupId":"OG001","value":"14.20","spread":null},{"groupId":"OG002","value":"0.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Seroprotected (SPR) Subjects With Anti-diphtheria Toxoid (Anti-DT) Antibody Concentrations Above the Predefined Cut-off Values","description":"Antibody concentrations cut-off values were ≥ 0.1 international units per milliliter (IU/mL) as assessed by enzyme-linked immunosorbent assay (ELISA) or ≥ 0.016 IU/ml as assessed by Vero cell neutralization test if concentrations were \\< 0.1 IU/ml when assessed by ELISA.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in international units per milliliter (IU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.126","spread":null},{"groupId":"OG001","value":"0.137","spread":null},{"groupId":"OG002","value":"0.134","spread":null},{"groupId":"OG003","value":"0.124","spread":null},{"groupId":"OG004","value":"0.168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.705","spread":null},{"groupId":"OG001","value":"5.003","spread":null},{"groupId":"OG002","value":"5.297","spread":null},{"groupId":"OG003","value":"5.777","spread":null},{"groupId":"OG004","value":"9.269","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Seroprotected (SPR) Subjects With Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Above the Predefined Cut-off Values","description":"Antibody concentrations cut-off value was ≥ 0.1 international units per milliliter (IU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"97.4","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-TT Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in international units per milliliter (IU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.709","spread":null},{"groupId":"OG001","value":"0.648","spread":null},{"groupId":"OG002","value":"0.617","spread":null},{"groupId":"OG003","value":"0.537","spread":null},{"groupId":"OG004","value":"0.566","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.313","spread":null},{"groupId":"OG001","value":"18.942","spread":null},{"groupId":"OG002","value":"12.531","spread":null},{"groupId":"OG003","value":"13.125","spread":null},{"groupId":"OG004","value":"10.792","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Seroprotected (SPR) Subjects With Anti-Bordetella Pertussis Toxoid (Anti-BPT) Antibody Concentrations Above the Predefined Cut-off Value","description":"Antibody concentrations cut-off value was ≥ 15 ELISA units per milliliter (EL.U/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"97.4","spread":null},{"groupId":"OG004","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-BPT Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"10.5","spread":null},{"groupId":"OG002","value":"10.6","spread":null},{"groupId":"OG003","value":"10.5","spread":null},{"groupId":"OG004","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.1","spread":null},{"groupId":"OG001","value":"115.9","spread":null},{"groupId":"OG002","value":"129.1","spread":null},{"groupId":"OG003","value":"112.6","spread":null},{"groupId":"OG004","value":"102.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Seroprotected (SPR) Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above the Predefined Cut-off Value","description":"Antibody concentrations cut-off value was ≥ 10 international units per milliliter (IU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"90.8","spread":null},{"groupId":"OG002","value":"94.7","spread":null},{"groupId":"OG003","value":"90.2","spread":null},{"groupId":"OG004","value":"81.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"97.5","spread":null},{"groupId":"OG002","value":"98.7","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"96.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations","description":"Antibody concentrations were presented as Geometric Mean Concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"91.2","spread":null},{"groupId":"OG002","value":"95.0","spread":null},{"groupId":"OG003","value":"84.4","spread":null},{"groupId":"OG004","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3451.8","spread":null},{"groupId":"OG001","value":"7801.4","spread":null},{"groupId":"OG002","value":"6547.7","spread":null},{"groupId":"OG003","value":"7265.8","spread":null},{"groupId":"OG004","value":"3334.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"61","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever \\[defined as axillary temperature equal to or above 38.0 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"29","spread":null},{"groupId":"OG004","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"29","spread":null},{"groupId":"OG004","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":249},"commonTop":["Pain","Irritability","Somnolence","Erythema","Pyrexia"]}}}